MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

At its core, conservation is about behavior change. Yet few organizations have put in place the structure, standards, and ...

Platform-specific achievement systems transformed an isolated gameplay preference into a visible, competitive subculture. What emerged wasn’t just a playstyle but an ecosystem of tracking tools, ...

This study provides important evidence that negative affect is associated with slower cognitive processing in daily life, with findings replicated across three independent samples and supported by ...

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials.

Recent research published in the journal Political Behavior shows that Americans largely prioritize the severity of a violent ...

It wasn't exactly a surprise after months of leaks and speculation, but Nvidia CEO Jensen Huang (in perhaps his finest ...

When AI-assisted coding is 20% slower and almost half of it introduces Top 10-level threats, it’s time to make sure we're not ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As compared with fulvestrant alone, the combination more than doubled the median ...

Main outcome measures Cumulative time dependent intake of preservatives, including those in industrial food brands, assessed using repeated 24 hour dietary records and evaluated t ...

Creature collecting games are having a major moment right now, but one upcoming title feels especially promising in the wake ...